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EFFECTS OF SIRTUIN 1 ON ARTERIAL STIFFENING 
IN A MODEL OF DIET-INDUCED OBESITY  
LEONA AL SAYAH 
ABSTRACT 
 
Background: Arterial stiffness, or the loss of compliance of the large arteries, is a major 
independent predictor of cardiovascular events. Obesity induced by a high fat, high 
sucrose (HFHS) diet, in mice, causes the development of arterial stiffness, diabetes, and 
hypertension. Along with the resulting metabolic syndrome, inflammation and oxidants 
are increased in vascular smooth muscle (VSM) cells of HFHS-fed mice. Sirtuin 1 
(SirT1), an important cellular homeostatic regulator, has been shown to prevent 
inflammation and obesity-associated metabolic impairment in animal models. This 
deacetylase is involved in histone and transcription factor regulation, thereby affecting a 
wide range of physiological mechanisms. However, whether SirT1 affects obesity-
induced arterial stiffness is unknown. Therefore, we aimed to investigate the effects of 
SirT1 on arterial stiffening in a setting of diet-induced obesity. 
 
Methods: The polyphenolic SirT1 activators, resveratrol and S17834, were added to 
HFHS diet fed to WT mice for 8 months. Arterial stiffness was measured in vivo, by 
pulse wave velocity (PWV), at baseline, 4 months, and 8 months. In another experiment, 
a highly selective SirT1 activator, SRT1720, was administered to mice in HFHS diet for 
one week following 8 months of HFHS diet, and PWV was measured before and after 
treatment. To study the role of VSM SirT1 in HFHS-induced arterial stiffness, resveratrol 
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was supplemented to HFHS diet-fed mice lacking SirT1 in VSM (SMKO), and PWV was 
measured in comparison to control HFHS-fed mice. Additionally, mice overexpressing 
SirT1 in VSM specifically (SMTG) were generated and placed on HFHS diet, and PWV 
was measured at baseline, 4 months, and 8 months. The effects of SirT1 on oxidant 
production and inflammation in the different experimental groups were assessed by 
staining aortic sections for oxidants and performing Western blots of inflammatory 
markers (phospho-p65 NFκB, VCAM1) on isolated aortic and VSM cell lysates.   
 
Results: Administering resveratrol and S17834 completely prevented the development 
HFHS-induced arterial stiffness over 8 months. Similarly, elevated PWV due to 8 months 
of HFHS diet was reversed by one-week treatment with SRT1720. SirT1 knockout in 
VSM partially prevented resveratrol’s effect in lowering arterial stiffness. Mice 
overexpressing SirT1 in VSM (SMTG) did not develop arterial stiffness and were 
protected from HFHS-induced oxidant production and inflammation (upregulation of 
phospho-p65 NFκB and VCAM1).  
 
Conclusions: VSM SirT1 can prevent the development of arterial stiffness in settings of 
obesity by opposing oxidants and inflammation in the aortic wall. SirT1 activators 
represent a potential therapeutic approach to alleviate the burden of cardiovascular 
disease in obese individuals with metabolic syndrome. 
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INTRODUCTION 
 	 Cardiovascular disease (CVD) remains the leading cause of mortality in 
the United States, accounting for over a fourth of all deaths annually (Centers for Disease 
Control and Prevention, 2015).  Overweight and obesity are prominent risk factors for 
CVD (Mozaffarian et al., 2016). The primary causes of obesity are diets rich in fat and 
sucrose compounded with sedentary lifestyles (Chaput & Tremblay, 2009; Cheung & Li, 
2012). Obesity is associated with a cluster of conditions, collectively termed the 
metabolic syndrome, that increase the risk for CVD. These include high triglyceride 
levels, low high-density lipoprotein (HDL) cholesterol levels, high fasting blood glucose, 
high blood pressure, and a large waistline (Katzmarzyk et al., 2005). There are currently 
over 78 million adults in the United States classified as obese, who consequently suffer 
from obesity-related conditions such as Type 2 diabetes mellitus (T2DM), coronary heart 
disease, and hypertension (Ogden et al., 2014). 
Maintaining normal blood pressure is fundamental for optimal organ function, 
and its regulation is essential to avoid reaching detrimental hypertensive levels. 
Hypertension, which is defined as systolic blood pressure ≥ 140 mmHg and/or diastolic 
blood pressure ≥ 90 mmHg, is a major risk factor for deadly CVD (Koeppen & Stanton, 
2009). High blood pressure can lead to end organ damage and greatly increase the risk for 
myocardial infarction and stroke. Caloric restriction and weight loss are successful in 
reversing the metabolic syndrome and stabilizing blood pressure, yet long term 
compliance in lifestyle modifications in the obese is very low and must be complemented 
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with medication or surgical intervention (Chaput & Tremblay, 2009). Studies that address 
risk factors for hypertension and novel therapeutic approaches for its prevention or 
amelioration can aid in greatly reducing the burden of CVD in obese patients with 
metabolic syndrome.  
 
Arterial Stiffness 
 Arterial stiffness, or the loss of elasticity of the large conduit vessels, is an 
independent risk factor for CVD, as demonstrated in multiple population studies (Sutton-
Tyrell et al., 2005; Najjar et al., 2008). As blood is ejected from the heart, the ability of 
the aorta to distend in response to changing volume is crucial for maintaining appropriate 
blood pressure and delivery. Aortic compliance is essential for dampening the pulsatile 
force of cardiac contraction and achieving steady organ perfusion. The Windkessel effect 
is the phenomenon exhibited by the distension of the elastic aorta due to the ejected blood 
and its recoil during diastole. As the aorta stiffens and loses the ability to handle pressure 
fluctuations, this Windkessel effect is lost, leading to deleterious consequences in 
downstream organs. Impairment of aortic compliance results in a wider pulse pressure, 
coupled with an increased cardiac afterload, for which the heart compensates by 
increasing workload. As a result, functional damage can occur to the heart and 
downstream organs and vasculature. 
Vascular remodeling and the rearrangement of vascular extracellular matrix are 
among the major adaptive mechanisms to chronic increases in blood pressure (Koeppen 
& Stanton, 2009). It has been suggested that in order to adapt to changes in hemodynamic 
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load due to chronically high blood pressure, arterial remodeling and stiffening occur in 
addition to vascular smooth muscle cell (VSMC) hypertrophy (O’Rourke et al., 2007). 
However, it is not clear whether aortic remodeling and stiffening precede or are a 
consequence of for hypertension. In recent epidemiological studies that adjusted for risk 
factors such as body mass index, age, sex, and blood pressure, arterial stiffness emerged 
as an independent predictor of hypertension (Mitchell et al., 2010). Although the cellular 
and molecular mechanisms of arterial stiffness are not fully elucidated, these studies 
indicate that aortic wall stiffening may play a causative role in hypertension 
development, and could therefore be therapeutically targeted to prevent associated CVD. 
Pulse wave velocity (PWV), or the rate at which pressure waves move along the 
aorta, is the gold standard method for measuring arterial stiffness in vivo. It is a highly 
reliable parameter that has been validated in multiple human studies and experimental 
models (Sutton-Tyrell et al., 2005; Najjar et al., 2008). A large study of the general 
population established that elevated PWV precedes an increase in systolic blood pressure 
and newly diagnosed hypertension (Sutton-Tyrrell et al., 2005). Individuals with higher 
PWV were at much greater risk of having a major CVD event such as a stroke (Mitchell 
et al., 2010). In addition to being predictive of hypertension, stroke, heart attack, and 
cardiac failure, PWV has recently emerged as a prognostic measure for cognitive 
impairment and kidney failure (Mattace-Raso et al., 2006; Willum-Hansen et al., 2006; 
Mitchell et al.; 2010, Kaess et al., 2012; Alghatrif et al., 2013; Ding et al., 2015; Pase et. 
al, 2016; Tsao et. al, 2015; Tsao et al., 2016). Furthermore, obese and diabetic patients 
show increased arterial stiffness even at young ages ranging from 10-24 years (Sutton-
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Tyrell et al., 2001). Conversely, weight loss in overweight and obese individuals is 
associated with a reduction in arterial stiffness (Dengo et al., 2010). This suggests that 
arterial stiffness, in the setting of metabolic syndrome, is a diseased state not wholly 
pertaining to vascular changes that accompany normal aging processes. 
To determine the mechanisms of arterial stiffening and reversal in settings of 
obesity, structural changes occurring in vessels of an animal model mimicking the human 
metabolic syndrome can be assessed. Compared to mice fed a normal diet (ND), mice fed 
a high fat, high sucrose (HFHS) diet closely recapitulate the human metabolic syndrome, 
progressively developing insulin resistance, increased body weight, and increased PWV 
followed by elevation of blood pressure (Weisbrod et al., 2013).  Interestingly, returning 
obese mice to ND for 4 months, after 5 months of HFHS, completely reverses metabolic 
and vascular parameters back to normal values (Weisbrod et al., 2013). This suggests that 
at least some determinants of arterial stiffness are reversible and that targeting arterial 
stiffening could be impactful in preventing the impairment of cardiovascular function in 
obese individuals. 
 
Sirtuin 1 
Sirtuin 1 (SirT1) is an evolutionarily conserved enzyme that has been implicated 
in the cellular response to metabolic, inflammatory, and oxidative stresses. This NAD+-
dependent deacetylase is considered an important metabolic regulator with beneficial 
effects against the production of damaging reactive oxygen species (ROS) and 
inflammatory processes associated with the pathophysiology of T2DM (Zhou et al., 
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2011). SirT1 is a class III histone deacetylase (HDAC) that can modulate nuclear 
heterochromatin and directly deacetylate an array of transcription factors involved in 
numerous cellular processes (Hayashida et al., 2010; Gillum et al., 2011).  
The effects of SirT1 have been tested in several mouse models of aging and 
obesity. Mice engineered to overexpress SirT1 and fed a high calorie diet or inbred into 
an obesity-prone db/db genetic background are protected from diabetes (Banks et al., 
2008). Additionally, pharmacologically inducing SirT1 expression can increase insulin 
sensitivity in diabetic mice (Sun et al., 2007). Although many studies have shown 
metabolic improvements involving hepatic processes upon SirT1 activation, the effects of 
SirT1 on the cardiovascular complications of diabetes are not well understood. 
Subsequently, our laboratory aimed to investigate the effects of SirT1 on arterial stiffness 
in a model of diet-induced obesity. 
 
Sirtuin 1 Activators 
 Resveratrol, a polyphenol found in red grapes, is known to activate SirT1 and 
produce beneficial effects in multiple disease conditions (Baur & Sinclair, 2006). 
Resveratrol has been shown to improve overall health, cell survival, aortic wall 
morphology, and insulin-resistance in mice fed high-calorie diets (Baur, 2010). However, 
the therapeutic potential of resveratrol and other polyphenolic compounds as anti-diabetic 
drugs has been controversial because of non-SirT1-mediated actions (Guo et al., 2015). 
Although studies have linked resveratrol benefits to the activation of hepatic and anti-
apoptotic pathways, among others, none have directly linked its effect on vascular 
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function specifically through SirT1 actions.  
Another polyphenol, S17834, is a synthetic flavonoid shown to have beneficial 
cardiovascular effects in T2DM settings (Qin et al., 2012). S17834 is a benzo(b)pyran-4-
one derivative that targets NADPH oxidase and opposes superoxide anion production in 
aortas of atherosclerotic mice (Cayatte et al., 2001). Additionally, it has been shown to 
decrease TNFα-induced vascular adhesion molecule 1 (VCAM1) expression in 
endothelial cells (Cayatte et al., 2001). Its clinical relevance lies in its ability to decrease 
superoxide anion levels by 40% and aortic atherosclerotic lesions by 60% in 
apolipoprotein E-deficient mice (Cayatte et al., 2001). Similarly to resveratrol, studies 
have linked S17834 to non-SirT1 mediated pathways, specifically via adenosine 
monophosphate-activated protein kinase (AMPK) (Zang et al., 2006). AMPK and SirT1 
have been implicated in similar processes of cellular metabolism, inflammation, and 
mitochondrial function, and are believed to share many common target molecules 
(Ruderman et al., 2010). 
A more highly selective SirT1 activator, called SRT1720, has been recently 
developed and explored. SRT1720 was shown to improve the health span and survival of 
obese mice, similarly to the aforementioned polyphenols (Minor et al., 2011). It was also 
found to downregulate NFκB and inflammatory cytokine expression, thus acting as an 
anti-inflammatory analgesic, in a rat model of chronic neuropathic pain (Lv et. al, 2015). 
In vascular studies, SRT1720 was found to reverse endothelial dysfunction in aging mice 
by reducing superoxide production and subsequent oxidative stress and inflammation 
(Gano et al., 2014). Consequently, our studies sought to elucidate the role of SirT1 in 
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obesity-induced arterial stiffness and the therapeutic potential of SirT1 activators against 
the cardiovascular complications associated with the metabolic syndrome. 
 
Previous Laboratory Findings 
We previously demonstrated that mice fed a HFHS diet attain a state that closely 
resembles the human metabolic syndrome, and develop arterial stiffness within two 
months, preceding the rise in systolic arterial pressure by five months (Weisbrod et al., 
2013). Aortic wall stiffening was associated with enhanced cytokine TNFα-induced 
inflammation and decreased nitric oxide (NO) bioavailability, leading to functional 
impairment of vascular smooth muscle (VSM) cells and increased extracellular matrix 
remodeling (Weisbrod et al., 2013).  
Increased inflammation and reactive oxygen species (ROS) can impair VSM 
function, and along with reduced vascular NO bioavailability, contribute to arterial 
stiffness and CVD (Lyle & Griendling, 2006; Park & Lakatta 2012). Among the many 
biological functions of NO on blood vessels, one is to regulate transglutaminase 2 (TG2) 
activity in the aortic wall. TG2, a Ca2+-dependent enzyme that catalyzes a transamidation 
reaction to form strong N-ε-(γ-glutamyl)-lysine bonds between extracellular matrix 
proteins, becomes more active in forming matrix crosslinks in settings of low NO 
bioavailability (Jandu et al., 2011). Our previous study found that HFHS diet reduces NO 
bioavailability, as indicated by impaired acetylcholine-induced aortic relaxation 
responses, and increases TG2 activity in aortas of obese mice, resulting in increased 
extracellular matrix crosslinks and increased arterial stiffness (Weisbrod et al., 2013).  
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In addition to decreased NO bioavailability and extracellular matrix crosslinks, 
we found that sulfonylation of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), a 
marker of oxidant stress, increased in aortas of HFHS-fed mice compared to ND 
(Weisbrod et al., 2013). Oxidative post-translational modifications, such as sulfonylation 
of SERCA at cysteine 674 (oxSERCA), prevent NO-mediated SERCA-dependent Ca2+ 
uptake into the sarco/endoplasmic reticulum, and thus impair VSMC relaxation. 
Therefore, impaired SERCA activity in settings of HFHS-induced oxidant stress could 
contribute to arterial stiffness by increasing VSM tone. We further demonstrated that 
HFHS diet increased TNFα-induced activation of the oxidant-generating enzyme 
NADPH oxidase 2 (Nox2) in aortas of obese mice (Qin et al., 2014). Nox2-derived 
oxidants caused p65-NFκB phosphorylation, VCAM1 upregulation, and functional 
impairment of aortic VSM cells (Qin et al., 2014). Most notably, aortic extracellular 
matrix crosslinks, oxSERCA, PWV, and high blood pressure were all decreased after 
reversal to ND. This suggested that processes of aortic stiffness are, at least in part, 
reversible and amenable to therapeutic pharmacological or life-style interventions 
(Weisbrod et. al, 2013). 
 Finally, we recently demonstrated that knocking out SirT1 from VSM in mice 
leads to aortic dissection in response to angiotensin II (Fry et al., 2015), indicating that 
VSM SirT1 has a pivotal role in maintaining the structural and functional integrity of the 
aortic wall in response to inflammatory and oxidant stimuli. 
Aims of Present Study 
 In the current study, we sought to explore the role of SirT1 in diet-induced arterial 
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stiffness and to evaluate the therapeutic potential of SirT1 activators against arterial 
stiffness in settings of obesity. By using multiple pharmacological and genetic 
interventions, along with our established model of diet-induced obesity, we sought to 
determine the effects of SirT1 on obesity-induced arterial stiffness and the molecular 
mechanisms involved, mainly oxidant production and inflammation in the aorta and in 
VSM cells. 
Specifically, the aims of this study were to: 
1) Determine the effects of SirT1 activators resveratrol, S17834, and SRT1720 on 
HFHS-induced arterial stiffness. 
2) Determine the effects of knocking out SirT1 in VSM (SMKO) on HFHS-induced 
arterial stiffness. 
3) Determine the effects of VSM cell SirT1 overexpression (SMTG) on HFHS-
induced arterial stiffness. 
4) Determine the effects of increased SirT1 activation on HFHS-induced oxidant and 
inflammatory markers in the aorta and in VSM cells. 
Seeking to elucidate the underlying cellular mechanisms of arterial stiffness may lead to 
additional options for prevention and treatment of hypertension and associated 
cardiovascular complications in obese individuals with metabolic syndrome. This could 
be very beneficial clinically in decreasing mortality associated with CVD and reducing 
the burden of disease.
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METHODS 
 
Animal models 
 The institutional animal care and use committee (IACUC) at Boston University 
Medical Campus approved all mouse protocols. Genetically engineered mice with SirT1 
knocked out (SMKO) or overexpressed in VSM (SMTG) were developed in house, as 
described in detail in our recent study (Fry et al., 2015). C57Bl/J6 (Jackson Laboratories) 
or littermate controls served as experiment controls. Mice were housed in groups of 3-4 
and supplied with food and water ad libitum. At 2 months of age, mice were fed ND or 
HFHS diets containing matching micronutrients except for fat and sucrose. Normal diet 
(ND) contains 4.5% fat and 0% sucrose (D09071702, Research Diets), while HFHS diet 
is composed of 35.5 % lard fat and 16.4 % sucrose (D09071703, Research Diets). Body 
weights were recorded at baseline and every month after diet initiation for 8 months. 
 
Pharmacological treatments 
 Three different SirT1 activators were administered in HFHS diet to mice. 
Firstly, resveratrol was supplemented in HFHS diet over 8 months at a daily dose of 130 
mg/kg/day. Resveratrol was dissolved in ethanol then blended with HFHS diet. 
Evaporation of ethanol was ensured by drying out the mixture for 48 hours before feeding 
to mice. In a similar manner, S17834 was dissolved in ethanol and admixed with food for 
a daily dose of 130 mg/kg/day, with ethanol evaporation for 48 hours.  
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 A subset of mice that were fed HFHS diet for 8 months then received HFHS 
containing SRT1720 for one week. SRT1720 was suspended in ethanol, sonicated until 
complete dissolution, then mixed into HFHS diet for a daily dose of 100mg/kg/day. As 
with resveratrol and S17834, ethanol was fully evaporated before feeding to mice.  
 
Pulse wave velocity (PWV) measurements 
 PWV measurement is based on a pressure wave’s arrival times at two different 
locations along the aorta that are a known distance apart. For the duration of the 
procedure, mice are kept anesthetized with 1-2% isofluorane to maintain constant blood 
pressure and heart rates throughout the measurement and to ensure similar levels in all 
experimental groups. PWV was assessed by Doppler ultrasound (Vevo770, Visualsonics) 
by recording flow waveforms at a proximal and a distal location along the aorta with 
simultaneous electrocardiogram (ECG) recordings. The distance between the proximal 
and distal points was measured. The arrival times for the proximal and distal locations, 
which represent the time between the R wave of the ECG corresponding to cardiac 
ventricular contraction, and the foot of each blood waveform, were measured manually 
and averaged over 5-10 cardiac cycles. PWV was calculated by dividing distance over the 
difference between the arrival times (m/s).  
 PWV was measured for the following groups after being placed on diet: 
- WT/ND (n=6), WT/HFHS (n=6), WT/HFHS/resveratrol (n=6) at baseline, 4, 8 months  
- WT/ND (n=6), WT/HFHS (n=6), WT/HFHS/S17824 (n=6) at baseline, 4, 8 months 
- WT/HFHS (n=4), WT/HFHS/SRT1720 (n=5) at 8 months and after 1 week of drug 
	12 
- WT/HFHS (n=6), WT/HFHS/resveratrol (n=9), SMKO/HFHS (n=6), and 
SMKO/HFHS/resveratrol (n=5) at 8 months  
- WT/HFHS (n=4), SMTG/HFHS (n=6) at baseline, 4, 8 months 
 
Aortic and VSM cell isolations 
 Mice were euthanized by isofluorane overdose and neck dislocation, and 
perfused with phosphate buffered saline (PBS) before dissection under microscope. 
Aortas, from the aortic arch to the iliac bifurcation, were cleaned from fat and blood, snap 
frozen in liquid nitrogen, and kept at -80°C until further processing.  
 Vascular smooth muscle (VSM) cells were isolated from cleaned aortas by 
enzymatic dissociation. Aortas were incubated at 37°C for 12 minutes in serum-free 
Dulbecco’s modified Eagle medium (DMEM) containing 3 mg/ml collagenase II 
(Worthington). Afterwards, the outer adventitial layer was removed manually, and the 
medial layer was placed in 3 mg/mL collagenase and 1 mg/mL elastase at 37°C for 30 
minutes, with agitation every 10 minutes. Cells were centrifuged and cultured in 
complete growth medium (DMEM 1 g/L glucose with 10% fetal bovine serum and 1% 
antibiotic) in a 37ºC incubator and used until the tenth passage. 
 
Real-time quantitative PCR 
 Total RNA was extracted from WT and SMTG aortas by standard methods of 
chloroform separation and isopropanol precipitation. Messenger RNA retro-transcription 
to cDNA was performed with a high capacity RNA to cDNA kit (Applied Biosystems). 
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SirT1 gene expression was analyzed by qRT-PCR with Taqman assays and an AB750 
instrument (Applied Biosystems). The endogenous control used was β-actin, and 
Microsoft Excel was used to analyze results using the ΔΔCt method. Relative SirT1 
mRNA quantity in SMTG aortas was normalized by β-actin and graphed relative to WT 
mice. 
 
 Experiments with cultured aortas and isolated VSM cells 
 TNFα (Peprotech) was prepared by dissolution in complete culture medium 
(DMEM 1g/L glucose with 10% fetal bovine serum) at a stock concentration of 10 µg/ml. 
Isolated aortas were placed in 1 ml culture medium with TNFα, at 10 ng/ml final 
concentration, in a 37°C incubator overnight. In subsets of experiments, SRT1720 (50 
µmol/L, Sellekchem) was added to the overnight incubation. Following incubation, aortas 
were washed in cold PBS, snap-frozen in liquid nitrogen, and kept at -80°C for later 
homogenization for Western blots. 
 Starving medium (DMEM 1g/L glucose with 0.1% fetal bovine serum) was 
added to isolated WT and SMTG VSM cells 24 hours prior to addition of treatment. 
Afterwards, 5 ml of fresh medium containing TNFα (10 ng/ml) or medium vehicle 
control were added. Cells were incubated overnight at 37ºC before collection in PBS and 
homogenization for Western Blots.  
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Western blots  
Frozen aortas or VSM cells from WT and SMTG mice were lysed in RIPA buffer 
(200 µL/1 mg, Cell Signaling Technologies) with freshly added protease inhibitor 
cocktail (5 µM) and trichostatin A (5 µM). Aortas were manually homogenized in a 
glass-glass grinder (Kontes) containing RIPA buffer and left on ice for 30 minutes to 
allow complete dissolution of proteins. Homogenates were then sonicated thrice for 10 
seconds each and kept on ice for 15 mins. To remove insoluble material, lysates were 
centrifuged at 4ºC for 10 minutes at 13,200 rotations per minute. Cleared lysates were 
then stored at -80ºC. 
A Pierce BCA Protein Assay kit (Thermo Scientific) was used to determine the 
protein concentration in the aortic and cell lysates, as per manufacturer instructions. After 
determining concentrations, 30-60 µg of protein were mixed with appropriate volumes of 
6x reducing Laemmli buffer and placed at 95ºC for 8 minutes for complete denaturation. 
Samples were then stored at -80ºC until Western blotting. 
 Aortic and VSM cell homogenates were resolved by SDS-PAGE using 4-20% 
polyacrylamide gels (105 V, 120 minutes) and transferred to nitrocellulose membranes 
(120mA, 120 minutes). Membranes were blocked in 5% non-fat milk prepared in 1% 
Tween-20 in TBS (TBS-T) for 1 hour. Membranes were then incubated with one of 
following antibodies overnight at 1:1000 dilution: SirT1 (ab110304, Abcam), acetylated 
histone H3 (9649S, Cell Signaling Technologies), phosphorylated p-65 NFκB (3033S, 
Cell Signaling Technologies), VCAM1 (14694, Cell Signaling Technologies), or β-actin 
(A5441, Sigma-Aldrich). After overnight incubation in cold room, membranes were 
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washed in TBS-T thrice for 5 minutes each, then incubated with peroxidase-conjugated 
anti-mouse or anti-rabbit secondary antibodies (Cell Signaling Technologies) for 1 hour. 
Membranes were then washed with TBS-T thrice for 5 minutes each and exposed to the 
chemiluminescent substrate ECL (General Electric Healthcare) to visualize protein bands.  
Band image documentation was processed with ImageQuant LAS4000 (General 
Electric). After imaging, some membranes were washed with stripping solution Re-blot 
Plus (Thermo Scientific) for 30 minutes, blocked in 5% milk-TBS-T for 1 hour, and re-
incubated overnight with appropriate antibody, as needed. The loading control used was 
β-actin and all protein band intensities were quantified with Image J (www.nih.gov). 
Intensities were averaged and normalized to β-actin per experimental group and 
expressed as fold change relative to WT controls. 
 
Aortic oxidant staining 
Dihydroethidine (DHE) was used to assess the amount of oxidants, mainly 
superoxide anion, in freshly frozen aortic sections. Aortas from 8-month-old WT mice on 
ND (n=5), HFHS (n=5), and HFHS with one week of SRT1720 (n=4) were used. For 
each aorta, 1 cm in length was frozen in OCT and kept at -80°C for sectioning with a 
cryotome at 10 µm thickness. The DHE solution was prepared fresh at 10 µM working 
solution. Aortic sections were washed on ice with cold PBS and incubated with DHE at 
37ºC for 45 minutes. Sections were then washed in PBS and cover-slipped with Prolong 
Gold Antifade mounting medium (Life Technologies).  
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Digital images were captured with an epifluorescent microscope (Nikon Eclipse 
80i), a CDD camera (DQ Qi Mc), and visualized with Nikon’s NIS-Elements 3.22 
software. Six independent observers who were blinded to the experimental groups 
quantified DHE red fluorescence intensity. The scoring system was on a scale of 0-4, 
with 0 indicating the lowest intensity as per amount of red fluorescence observed in a 
section and 4 indicating the highest intensity. Scores pertaining to the same experimental 
group were averaged before statistical analysis and graphing.  
 
Statistical analysis  
 Data are expressed as mean ± SEM and analyzed with Microsoft Excel or 
GraphPad Prism. Repeated measures two-way ANOVA was used to analyze PWV in 
mice fed ND, HFHS, HFHS with resveratrol or S17834, and HFHS-fed SMTG mice 
during the 8-month time period. Nonparametric one-way ANOVA was used to analyze 
the values of PWV in SMKO mice with or without resveratrol, and for quantification of 
DHE staining. PWV in mice treated with or without SRT1720 was analyzed by an 
unpaired t-test. Since the Western blots and qRT-PCRs had n <7, the non-parametric 
Whitney-Mann t-test was used to compare the means of two groups. P values < 0.05 were 
considered significant.  
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RESULTS 	
Effects of polyphenolic SirT1 activators resveratrol and S17834 on HFHS-induced 
arterial stiffness 
 
HFHS diet fed to WT mice for caused an increase in arterial stiffness measured in 
vivo by PWV. Stiffness remained elevated above 4 m/s for up to 8 months compared with 
mice fed ND (Figure 1A, ND vs. HFHS). Along with stiffness, body weights increased 
(Figure 6) and mice became obese and glucose intolerant (not shown), indicative of 
metabolic syndrome.  
Supplementing HFHS diet with resveratrol at a dose of 130 mg/kg/day completely 
prevented the development of arterial stiffness as indicated by PWV values that remained 
comparable to ND-diet-fed mice at around 2-3 m/s, which is the normal range of PWV in 
healthy mice (Figure 1A, HFHS/Resv).  
Similarly, addition of S17834 to HFHS diet at a dose of 130 mg/kg/day prevented 
HFHS-induced PWV increases over the 8-month period, as PWV values remained similar 
as in mice fed ND (Figure 1B, HFHS/S17834).  
Both treatments were sufficient to prevent an increase in arterial stiffness without 
evident metabolic effects, as HFHS diet increased body weights in resveratrol or S17834-
treated mice to the same extent as HFHS-fed controls (Figure 6). 
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Figure 1. SirT1 activators resveratrol and S17834 protect from HFHS-induced 
arterial stiffness. Administering the polyphenolic compounds resveratrol (A) and 
S17834 (B) in HFHS diet for 8 months, each at a dose of 130 mg/kg/day, prevented 
HFHS-induced arterial stiffness measured in vivo by pulse wave velocity (PWV, m/s). *, 
p<0.05 ND (n=6) vs. HFHS (n=6). 
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Effects of selective SirT1 activator SRT1720 on HFHS-induced arterial stiffness 
 
 The small molecule SirT1 activator SRT1720 was mixed in food at a dose of 100 
mg/kg/day and administered to obese mice. Treatment with SRT1720 for one week, after 
8-month of HFHS diet, decreased high PWV back to normal values around 3 m/s (Figure 
2). 
 
 
 
 
 
 
 
 
 
 
Figure 2.  SirT1 activator SRT1720 improves HFHS-induced arterial stiffness. 
Treating obese mice with HFHS-induced arterial stiffness for one week with the selective 
SirT1 activator SRT1720, at a dose of 100 mg/kg/day, significantly decreased PWV 
values (m/s) back to normal. *, p<0.05 HFHS (n=4) vs. HFHS/SRT1720 (n=5). 
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Effects of knocking out VSM SirT1 (SMKO) on HFHS-induced arterial stiffness 
Feeding the HFHS diet to mice lacking SirT1 deacetylase activity in VSM 
(SMKO) resulted in PWV increases comparable to WT mice on HFHS diet (Figure 3, 
black bars). Resveratrol was effective in maintaining PWV at normal values in WT 
controls. Yet, lack of VSM SirT1 in SMKO partially abolished the beneficial effects of 
resveratrol on HFHS-induced arterial stiffness, although there was no statistical 
significance compared with WT mice on HFHS/Resv (Figure 3, orange bars).  
 
 
 
 
 
 
 
 
 
Figure 3. Knocking out VSM SirT1 (SMKO) attenuates the effects of resveratrol 
against HFHS-induced arterial stiffness. The beneficial effects of resveratrol against 
HFHS-induced arterial stiffness were partially lost in mice lacking VSM SirT1 (SMKO). 
*, p<0.05, WT/HFHS (n=6) vs. WT/HFHS/Resv (n=9) and SMKO/HFHS (n=6) vs. 
SMKO/HFHS/Resv (n=5); WT/HFHS/Resv (n=9) vs. SMKO/HFHS/Resv (n=5) not 
significant. 
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Characterization of SirT1 VSM overexpressing transgenic mice (SMTG) 
Mice genetically engineered to overexpress SirT1 in VSM have significant 
increase in SirT1 expression in both whole aortic extracts and VSM cells isolated from 
aortas. An increase in SirT1 expression is demonstrated by Western blot in WT vs. 
SMTG mice, and quantified as 4-fold by qRT-PCR relative to endogenous β-actin 
(Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Characterization of VSM SirT1 overexpression in mice (SMTG). Western 
blots from aortas and VSM cells isolated from WT and SMTG mice show differences in 
SirT1 expression. Quantitative RT-PCR for SirT1 indicates 4-fold increase in SMTG 
aortas (n=4) compared with WT (n=4). *, p<0.05. 
0
1
2
3
4
5 *
4x
Si
rT
1/
β-
ac
tin
 m
R
N
A
WT SMTG
WT SMTG 
SirT1 
β-actin 
VSMC 
SirT1 
β-actin 
WT SMTG 
Aorta 
	22 
Effects of VSM cell SirT1 overexpression (SMTG) on HFHS-induced arterial 
stiffness 
VSM SirT1 over-expression in SMTG mice had very similar effects as 
resveratrol, S17834 (Figure 1) and SRT1720 (Figure 2) on obesity-induced arterial 
stiffness. SMTG mice were protected from HFHS-induced PWV increases, for PWV 
values were significantly lower than WT controls over the course of 8 months of HFHS 
feeding (Figure 5).  
 
 
 
 
 
 
 
 
 
 
Figure 5. VSM SirT1 over-expression (SMTG) prevents HFHS-induced arterial 
stiffness. Mice over-expressing SirT1 in VSM (SMTG) were protected from arterial 
stiffness induced by HFHS diet. PWV values were decreased compared with HFHS-fed 
littermate controls (n=4). *, p<0.05 WT/HFHS (n=4) vs. SMTG/HFHS (n=6). 
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Effects of SirT1 activators on mouse body weight over time 
 Mouse body weights increased with HFHS diet regardless of SirT1 activation by 
resveratrol (Figure 6A), S17834 (Figure 6B), or SMTG (Figure 6C). Body weights of 
ND-fed mice increased over time but were significantly lower than HFHS-fed mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. SirT1 activation does not affect body weight of HFHS-fed mice. (A) Body 
weight gains over 8 months in mice fed ND (n=6), HFHS (n=6), or HFHS supplemented 
with resveratrol at 130 mg/kg/day (n=6). (B) Body weights of ND (n=6), HFHS (n=6), or 
HFHS supplemented with S17834 at 130 mg/kg/day (n=6). *, p<0.05 WT/HFHS vs. 
WT/ND; †, p<0.05 WT/HFHS/Resv or WT/HFHS/S17834 vs. WT/ND. (C) Body weights 
of WT (n=4) and SMTG (n=6) fed HFHS for 8 months. 
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Effects of VSM SirT1 overexpression on aortic inflammatory markers 
 VSM SirT1 overexpression prevented phosphorylation of p65-NFκB (active 
NFκB subunit) and TNFα-induced VCAM1 upregulation in whole aortas compared to 
WT controls (Figure 7). SirT1 enzyme activity in SMTG was significantly increased after 
TNFα stimulation, as demonstrated by decreased acetylated histone H3 when compared 
with non-treated aortas (Figure 7). 
 
 
 
 
 
 
 
 
 
 
Figure 7. SirT1 protects from inflammatory marker upregulation in the aorta. 
Representative Western blots for acetylated histone H3, phosphorylated p65 (active 
NFκB subunit), VCAM1, and β-actin in aortas of WT and SMTG mice treated overnight 
with or without TNFα (10 ng/ml). Each lane represents one aorta from one mouse. 
Western blots were repeated 6 times.  
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Effects of VSM SirT1 overexpression on VSM inflammatory markers 
Similar to the aorta, SirT1 over-expression prevented p65-NFκB phosphorylation 
and TNFα-induced VCAM1 upregulation in VSM cells. SirT1 deacetylation activity in 
VSM cells isolated from SMTG aortas was significantly increased after TNFα 
stimulation, as demonstrated by decreased acetylated histone H3 (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8. SirT1 protects from inflammatory marker upregulation in VSM cells. 
Representative Western blots for acetylated histone H3, phosphorylated p65 (active 
NFκB subunit), VCAM1, and β-actin in VSM isolated from aortas of WT and SMTG 
mice and treated overnight with or without TNFα (10 ng/ml). Western blots were 
repeated 6 times.  
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Effects of SirT1 activator SRT1720 on aortic inflammatory markers 
Addition of SRT1720 to aortas overnight decreased expression of active NFκB 
subunit phospho-p65, VCAM1, and acetylated histone H3, indicating that SRT1720 is 
effective in activating SirT1 in the aorta and preventing inflammatory marker 
upregulation (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. SirT1 activator SRT1720 decreases the expression of inflammatory 
markers in the aorta. Representative Western blots for acetylated histone H3, 
phosphorylated p65 (active NFκB subunit), VCAM1, and β-actin in aortas treated 
overnight with TNFα (10 ng/ml) and with or without SRT1720 (50 µmol/L). Each lane 
represents one aorta from one mouse. Western blots were repeated 3 times. 
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Effects of SirT1 on aortic inflammatory marker expression 
 
Figure 10. Western blot quantitation of SirT1 effects on aortic inflammatory 
marker expression. Quantitation of band intensities of Western blots depicted in Figure 
7 (A), Figure 8 (B), and Figure 9 (C). For each protein, the ratio with loading control β-
actin was calculated, averaged per treatment group, and expressed as fold change relative 
to WT controls. For (A) and (B) *, p<0.05 vs. WT/control; †, p<0.05 vs. WT/TNFα; #, 
p<0.05 vs. SMTG/control. For (C), *, p<0.05 vs. WT/TNFα. 
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Effects of SirT1 activator SRT1720 on HFHS-induced aortic oxidants 
Production of superoxide anion, assessed by DHE staining, was significantly 
increased in mice fed HFHS diet for 8 months compared to ND-fed mice. Conversely, 
oxidants were significantly decreased when obese mice were treated with SRT1720 for 
one week compared with WT HFHS-fed mice (Figures 11 and 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. SirT1 activator SRT1720 decreases HFHS-induced aortic oxidants. 
Representative images of DHE-stained aortic sections from WT/ND (n=5), WT/HFHS 
(n=10) and WT/HFHS/SRT1720 (n=4) mice. A rating on a scale 0-4 was used by 6 
investigators, blinded to the treatment groups, to quantitate oxidant staining.  
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Effects of SirT1 activator SRT1720 on HFHS-induced aortic oxidants 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Quantitation of HFHS-induced oxidants in the aorta. Quantitation of red 
fluorescence intensities, corresponding to DHE-stained oxidants, by scoring. Six 
independent investigators used a rating system with a scale of 0-4, with 0 corresponding 
to the lowest red fluorescence intensity and 4 to the highest. *, p<0.05 WT/HFHS vs. 
WT/ND; #, p<0.05 WT/HFHS/SRT1720 vs. WT/HFHS.  
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DISCUSSION 
 
 The progressive functional impairment of the large arteries, termed arterial 
stiffening, adds to the risk of developing CVD in the overweight and obese populations 
(Sutton-Tyrell et al., 2001). Mice fed HFHS diet become obese and develop metabolic 
syndrome that closely mimics the human pathophysiology, and thus serve as a good 
model to study obesity-associated cardiovascular complications (Weisbrod et al., 2013). 
In the aforementioned study, we found that HFHS-fed mice had significantly increased 
PWV, the in vivo index of arterial stiffness, within 2 months of HFHS diet initiation, and 
developed hypertension 5 months thereafter. Additionally, obese mice had larger aortic 
medial areas when compared with ND-fed mice, indicating aortic remodeling. 
Interestingly, PWV in returned to normal in obese mice placed back on ND for 4 months 
after 5 months of HFHS. Additionally, several markers of inflammation and oxidant 
production in the aorta returned to normal despite medial area remaining relatively 
unchanged, suggesting that some components of arterial stiffness are reversible. 
SirT1 is an evolutionarily conserved enzyme important for a variety of cellular 
functions including adaptation to metabolic stresses and caloric restriction. In the present 
study we set out to study the effects of SirT1 in HFHS-induced arterial stiffness by 
employing several in vivo and ex vivo approaches. Firstly, we administered two 
polyphenolic compounds known to activate SirT1, resveratrol and S17834, and one small 
molecule activator, SRT1720, to mice fed HFHS for up to 8 months. Polyphenols 
prevented aortic stiffness over the course of 8-month HFHS feeding (Figure 1).  
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Similarly, the non-polyphenolic small molecule activator, SRT1720, known to 
exert more potent effects and greater affinity for SirT1 than resveratrol, normalized 
arterial stiffness after just one week of administration to obese mice (Figure 2). Our 
results, if translated to humans, suggest that SRT1720 could be useful in the clinic to 
ameliorate arterial stiffness in overweight or obese individuals with metabolic syndrome, 
possibly preventing cardiovascular events in this patient population.  
  Interestingly, our studies demonstrated that the beneficial effects of SirT1 against 
obesity-induced arterial stiffness were mediated by vascular-specific mechanisms rather 
than a global metabolic effect. Since VSM is the major structural component of the aorta, 
we knocked out and overexpressed SirT1 specifically in VSM. The lack of SirT1 
deacetylase activity in VSM of SMKO mice partially abolished the beneficial effects of 
resveratrol against HFHS-induced PWV increases, suggesting that its actions are at least 
partially mediated through SirT1 in VSM cells (Figure 3). Consistent with these results, 
we found that mice overexpressing SirT1 in VSM (Figure 4) were also protected from 
HFHS-induced arterial stiffness over 8 months (Figure 5).  
Importantly, although studies by others indicated that resveratrol improves 
glucose intolerance and other indices of metabolic impairment, in part via SirT1-
independent pathways (Park et al., 2012), our work highlights that polyphenolic 
compounds could indeed be working through VSM SirT1 to improve arterial stiffness, as 
the effects of SirT1 activators were mimicked by mice over-expressing SirT1 in VSM. In 
addition, our findings indicated that SirT1 activation, regardless of pharmacological or 
genetic intervention, did not ameliorate metabolic indexes such as body weight (Figure 6) 
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and glucose intolerance (not shown) in obese mice. These findings are in contrast with 
studies by others showing that resveratrol improves insulin sensitivity and diabetes in 
obese mice (Banks et al., 2008; Pfluger et al., 2008). These apparent discrepancies are 
likely explained by different experimental approaches used by different laboratories. 
Specifically, we fed mice a diet rich in fat and sucrose over an 8-month period and 
compared it with a normal diet formulated to contain matched micronutrients except for 
fat and sucrose. On the other hand, other studies used diets high in fat, with normal 
sucrose content, and for a shorter duration of typically 4 months (Winzell et al., 2004, 
Banks et al, 2008; Prfluger et al., 2008; Mattison et al., 2014). In addition, these studies 
compared high fat-fed mice to standard chow-fed mice, rather than to a customized diet. 
The difference in feeding times and sucrose levels could account for differences in the 
observed metabolic effects. Importantly, our studies indicate that SirT1 might be working 
in a vascular-specific manner rather than just preventing or ameliorating stiffness via a 
global metabolic improvement. 
Building upon our previous work, which showed that HFHS diet stimulates the 
expression of inflammatory markers and oxidants in aortas of obese mice, we 
demonstrated that SirT1 can inhibit these pathways. Specifically, we found that VSM 
SirT1 overexpression inhibits NFκB activation and VCAM1 upregulation in aortas and 
VSM cells from SMTG mice (Figures 7 and 8). We assessed histone H3 deacetylation as 
an index of SirT1 activity in the aorta. Acetylated histone H3 was significantly decreased 
in SMTG aortas and VSM cells when stimulated by TNFα (Figures 7 and 8). Our results 
are consistent with studies by others showing that SirT1 deacetylation activity directly 
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inhibits NFκB activation and activates Nrf2, a transcription factor that upregulates 
antioxidant enzymes, such as superoxide dismutase 1 (SOD1) (Huang et al., 2013). 
Indeed, preliminary studies (not shown) indicate that SOD1 is modestly increased in 
SMTG aortas, however further studies are warranted to confirm such effects. 
Alternatively, it is possible that VSM SirT1 could be inhibiting sources of 
oxidants, in addition to inducing antioxidant systems, in aortas of obese mice. We 
previously showed that NADPH oxidase Nox2 is a major source of oxidants in VSM 
cells from HFHS-fed mouse aortas (Qin et al., 2013). Thus, SirT1 may be inhibiting 
Nox2, as well as other oxidant sources such as Nox1 or Nox4, which are abundant in the 
aortic wall in diseased states (Matsumoto et al., 2003; Lyle & Griendling, 2006; Tong et 
al., 2016).  
Oxidant visualization via DHE staining on aortic sections corroborated our 
hypothesis that SirT1 decreases oxidant production in the aortic wall. DHE fluorescence 
was abundant throughout the VSM in aortic sections from HFHS-fed mice, and was 
significantly decreased in aortas from 8 month-old HFHS-fed mice treated with SRT1720 
for one week (Figures 11 and 12). In addition to Nrf2, multiple other SirT1-mediated 
mechanisms may be at play in the aortic wall, resulting in decreased arterial stiffness. 
Since SirT1 can deacetylate a number of transcription factors, as well as histone H3, it 
can modulate heterochromatin and epigenetically affect multiple genomic programs (Hsu 
et al., 2016). 
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A summary of the postulated mechanisms by which SirT1 protects against HFHS-
induced arterial stiffness is illustrated in Figure 13 below.  
 
Figure 13. Postulated mechanisms of SirT1 action against arterial stiffness.  
Several pathways in the aortic wall synergistically contribute to aortic stiffness 
and can be inhibited by SirT1. Pharmacological treatment with resveratrol, S17834, 
SRT1720, or genetic interventions such as SMTG mice, result in decreased arterial 
stiffness by multiple and co-dependent mechanisms such as NFκB inhibition and 
decreased VCAM1 production, which decrease aortic inflammation. SirT1 can also 
oppose the deleterious effects of Nox2-derived oxidants, which are known to sequester 
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nitric oxide (NO), thus impairing VSM relaxation and stimulating enzymatic extracellular 
matrix cross-links via TG2, thereby contributing to aortic wall stiffening. Taken together, 
our results indicate that decreasing oxidant production and its downstream inflammatory 
effects via SirT1 can ameliorate aortic stiffness in settings of obesity. 
We employed multiple approaches to investigate the effects of SirT1 on arterial 
stiffening. Treatment with three different pharmacological SirT1 activators, genetic over-
expression, and ex vivo approaches all indicated that SirT1 opposed inflammatory and 
oxidant pathways to protect against HFHS-induced arterial stiffness (Figures 7-12). Our 
previous finding that reversal to ND improves vascular function (Weisbrod et al., 2013) 
suggests that targeting arterial stiffness with early pharmacological or lifestyle 
interventions could be a useful approach to prevent CVD in obese individuals with 
metabolic syndrome 
In conclusion, considering the current epidemic proportions of overweight and 
obesity in the US, it is crucial to develop novel therapies to prevent cardiovascular events 
in individuals affected by the metabolic syndrome. A better understanding of molecular 
mechanisms involved in obesity-induced arterial stiffness and their potential key 
regulators, such as SirT1 as indicated by our studies, is critical for the development of 
effective therapeutic strategies directed against arterial stiffness. By preventing arterial 
stiffness, SirT1 activators may also prove useful against the deleterious consequences of 
diabetes and hypertension on the function of highly perfused organs such as the brain and 
kidneys, which are susceptible to damage by excessive pressure, as well as the heart 
which hypertrophies due to excessive afterload caused by a stiff aorta.	  
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